Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 4Leukemia, Myeloid, Acute 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Breast Diseases 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Thrombocythemia, Essential 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Polycythemia Vera 1Ovarian Neoplasms 1Lymphedema 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hypogonadism 1Glioma 1Gastric Adenocarcinoma 1Fatigue Syndrome, Chronic 1Eunuchism 1Colorectal Neoplasms 1Amyloidosis 1Adenoma 1

Interventions

Paclitaxel 1Gemcitabine 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Serous Ovarian Cancer × Drug Evaluation × Clear all
NCT06055348 2023-09-26

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Unknown
112 enrolled
Gynecologic

Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡